3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Breast Neoplasms
5
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Unknown Primary
2
Lung Neoplasms
2
Carcinoma
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unresectable Stage III NSCLC
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Penile Neoplasms
1
Pathologic Complete Response
1
Ovarian Diseases
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Male Urogenital Diseases
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
First-line Advanced NSCLC Patients
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Endocrine System Diseases
1
Interventions
pembrolizumab
5
Nivolumab
4
Cisplatin
4
Paclitaxel
3
Ifosfamide
3
avelumab
2
aldesleukin
2
Radiotherapy
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
vinflunine
1
toripalimab
1
rocakinogene sifuplasmid
1
niraparib
1
nimotuzumab
1
lenvatinib
1
fludarabine phosphate
1
fludarabine
1
enfortumab vedotin
1
durvalumab
1
dostarlimab
1
dacomitinib
1
cemiplimab
1
cabozantinib
1
cabazitaxel
1
Vorinostat
1
VGX-3100
1
Specimen Handling
1
Ritonavir
1
Neoadjuvant Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Penile Neoplasms
×
CP protocol
×
Clear all
NCT06353906
2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2
Recruiting
27 enrolled